Montreal, Quebec, August 26, 2021 – Novartis Pharmaceuticals Canada Inc., in partnership with C2 International is hosting the first ever Biome Summit in Canada. A unique, collaborative multi-stakeholder platform, the Summit this year aims to address the pressing issue of cardiovascular disease across the country.
Read MoreNovartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Luxturna® (voretigene neparvovec), a one-time gene therapy for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. The presence of biallelic RPE65 mutations should be confirmed by an accredited laboratory using validated assay methods.
Read More
